splitting, provided no additional benefit in rate of return to racing and race performance.
Introduction

51
Superficial digital flexor (SDF) tendonitis is the most common cause of lameness in 52 National Hunt racehorses, with prevalences as high as 24% (Lam et al., 2007; Avella et al., 53 2009; Dyson et al., 2011) , or 1.71 per 100 horse months in training (Ely et al., 2009) . SDF 54 injuries require prolonged rehabilitation, with unpredictable outcomes and high incidences of 55 re-injury (Marr et al., 1993; O'Meara et al., 2010) . SDF tendonitis is often career ending 56 (Marr et al., 1993; Lam et al., 2007; Dyson et al., 2011) . (Silver et al., 1983; Marr and Bowen, 2012) . Tendon splitting to release the pressure of 63 haemorrhage and promote vascularisation in the injured area has yielded mixed results
64
(Stromberg. B et al., 1974; Henninger et al., 1990; Ross et al., 2011) . Desmotomy of the 65 accessory ligament of the superficial digital flexor tendon produced favourable rates of return 66 to racing and number of races completed but resulted in increased suspensory ligament strain 67 experimentally and higher incidence of suspensory ligament desmitis clinically (Bramlage, 68 1986; Bramlage, 2012) . Intralesional β-aminopropionitrile fumerate, polysulphated 69 glycosaminoglycans and sodium hyaluronate (Dowling et al., 2000) have been superceded by 70 regenerative therapies. Isolated exogenous growth factors such as insulin-like growth factor 1 71 and transforming growth factor-β can be administered intra-lesionally (Dowling et al., 2000; 72 Witte et al., 2011), however more recently mixed endogenous cytokines have been delivered 73 single treatment prospective studies therefore currently represent the best available evidence.
99
This observational case-control study compared racing outcomes in a population of National
100
Hunt racehorses in the Republic of Ireland. Outcomes were compared between injured horses 101 and control horses, and between treatments, for a range of contemporary and more traditional 102 therapies including thermocautery, which is still widely practised in spite of the ethical 103 considerations. We hypothesised that lesion severity would be correlated with racing 104 performance post-injury; that horses treated with PRP would more frequently return to 105 racing, and at a higher standard than horses treated by bar firing, controlled exercise, tendon 106 splitting or bar firing combined with tendon splitting; and that bar firing alone or in 107 conjunction with tendon splitting would provide no additional benefit for racing performance 
Materials and methods
111
Horses
112
All National Hunt racehorses that had competed over jumps under rules and were
113
presented to a single clinic between June 2007 and July 2011 for evaluation of an SDF 114 tendon injury were identified (Fig. 1) . Two age-and sex-matched horses were selected using 115 a random number generator from the starters of the last race prior to presentation for each 116 injured horse, to act as controls. Where identical matches were not available, the closest 117 matches were selected. If the treated horse had not yet raced, control horses were selected 118 from the first race after treatment.
120
Age, sex, horse origin (ex-store, ex-flat or point-to-point), lesion severity and 121 treatment were taken from hospital records. Lesions were defined ultrasonographically as 122 mild, moderate or severe (<10%, 10-40% or >40% of tendon cross-sectional area affected at 123 the zone of maximum injury; Smith and McIlwraith, 2012) .
124
Bar firing
136
This was undertaken under sedation with detomidine (0.01 mg/kg IV) and 137 butorphanol (0.01 mg/kg IV). Procaine penicillin (22000 IU/kg IM), gentamycin (6.6 mg/kg 138 IV) and phenylbutazone (4.4 mg/kg IV) were administered pre-operatively. High 4-point 139 regional anaesthesia and proximal cannon-bone ring block were performed on the affected 140 leg. Horizontal lines were scored at an interval of approximately 2 cm in the skin overlying 141 the palmar metacarpus. The glowing wire was placed against the skin, scalding the skin 142 superficially but taking care not to cause a full thickness skin defect. A bandage was applied 143 and changed every 48 h for 2 weeks. Horses received phenylbutazone (2.2 mg /kg PO twice 144 daily for 7 days). The standard 48-week exercise program was recommended (Table 1) .
Injection of platelet rich plasma
PRP was injected 2-3 weeks after injury. PRP was harvested using an Osteokine PRP 148 device (Dechra) and activated with calcium chloride prior to injection. Twenty-two to 25 149 gauge needles were placed throughout the length of the lesion under ultrasound guidance.
150
PRP was injected starting distally and proceeding proximally with final injection volume 151 determined by lesion size. A bandage was applied and changed every 48 h for 2 weeks.
152
Horses received phenylbutazone (4.4 mg /kg PO twice daily for 5 days) and procaine 153 penicillin (22000 IU/kg IM twice daily for 4 days), were box rested for 2 weeks and then the 154 standard 48-week exercise program was recommended (Table 1) .
156
Tendon splitting
157
Horses underwent tendon splitting 3-4 weeks after injury. This was undertaken under difference between point-to-point and ex-store groups (1.378 [0.516, 3.682] ; P = 0.523; Table   212 2) and only a marginal difference between point-to-point and ex-flat groups (3.463 [0.990, 213 12.112]; P=0.052).
215
Geldings represented 82% (n = 104) of the injured horses. The remainder were mares,
216
and sex was not correlated with horse origin (P = 0.363). Injured horses ranged in age from 217 3-11 years (median = 6), and age was not correlated with horse origin (P = 0.799).
219
The number of races prior to the injury date was not correlated with injured or control 220 status (P = 0.094; Table 2 ). Median pre-injury total race distance and median pre-injury 221 RPR max were not correlated with injured or control status (Table 2) .
223
Nine horses were retired from racing. Post-injury racing performance was analysed 224 for the remaining 118 horses. Overall, compared to control horses, injured horses had fewer 225 races, a shorter total distance and lower RPR max (Table 2) was longer for injured horses than control horses (P < 0.001; Table 2 ). Median and minimum
229
intervals between post-injury races did not differ significantly between injured horses and 230 control horses (P = 0.246, 0.108, respectively; Table 2 ), but maximum interval was 231 significantly shorter in injured horses (P < 0.001; Table 2 ). The timing of the largest interval 232 between races was interval 1 in injured horses and interval 4 in control horses (P < 0.001),
234
Lesion severity
235
Seventeen horses (13.4%) had mild lesions, 78 (61.4%) had moderate lesions and 32
236
(25.2%) had severe lesions. Lesion severity was not associated with horse origin (P = 0.496), 237 sex (P = 0.530) or age (P = 0.912), nor did it have a significant correlation with pre-injury 238 number of races (P = 0.338), pre-injury total race distance (P = 0.281) or median pre-injury
239
RPR max (P = 0.972; Table 6 ).
241
Treatment and racing performance
242
Treatment group was not associated with horse origin (P = 0.158; Table 3 ), age (P = 243 0.298) or sex (P = 0.152), but was significantly associated with lesion severity (P < 0.001; Table 3 ). Treatment group was not associated with pre-injury total race distance (P = 0.634),
245
number of pre-injury races (P = 0.384), or with pre-injury RPR max (P = 0.107; Table 4 ). Post-246 injury number of races and total race distance did not differ with lesion severity (P = 0.593 247 and P = 0.811, respectively; Table 6 ) or by treatment group (P = 0.480 and P = 0.480, 248 respectively; Table 4 ). Post-injury RPR max did not differ with lesion severity (P = 0.635; 249 Table 6 ). Overall post-injury rate of return to racing did not differ significantly by lesion 250 severity (P = 0.650; Table 7 ) or treatment group (P = 0.579; Table 5 ). Odds of racing three 251 times post-injury did not differ with lesion severity (P = 0.684, Table 7 ) or treatment group 252 (P = 0.068; Table 5 ). Odds of racing five times post-injury did not differ with lesion severity
253
(P = 0.765; Table 7 ) or treatment group (P = 0.730; Table 5 ).
255
Interval to first post-injury race did not differ with lesion severity (P = 0.918; Table 6 ). The timing of the largest interval between races in injured horses did not differ 260 significantly by treatment group (P = 0.822; Table 4 ) or by lesion severity (P = 0.288; Table   261 6). 1993). Injury severity also showed no significant association with post-injury RPR max .
286
Although increasing lesion severity increases the rate of retirement, it need not negatively 287 affect the post-injury racing performance of treated horses.
289
Cost and pre-injury racing standard are likely to influence treatment selection.
290
However, when comparing pre-injury racing standard across treatment groups, we found no 291 evidence that horses racing at a higher standard were overrepresented in any treatment group,
292
such as more expensive intralesional PRP.
We assessed career longevity by completion of three and five races post-injury as well Ely, E.R., Avella, C.S., Price, J.S., Smith, R.K., Wood, J.L., Verheyen, K.L., 2009. Horses with a full clinical history that also underwent a full evaluation were included in the study; n=127
SDF tendonitis but missing clinical data; n=51
No significant findings on ultrasound scan; n=9
Bilateral tendon lesion; n=14
Inciting cause was trauma; n=6
Race records unavailable; n=7
Concurrent problems; n=26
Treatment combinations outside of outlined categories; n=4
